This case-control study aims to compare the efficacy, safety, and postoperative burden of MicroShunt versus trabeculectomy. The first consecutive cohort of MicroShunt procedures (n = 101) was matched to recent historical trabeculectomy procedures (n = 101) at two London hospital trusts. Primary endpoints included changes in intraocular pressure (IOP) and glaucoma medications. Secondary outcome measures included changes in retinal nerve fibre layer (RNFL) thickness, rates of complications, further theatre interventions, and the number of postoperative visits. From the baseline to Month-18, the median [interquartile range] IOP decreased from 22 [17–29] mmHg (on 4 [3–4] medications) to 15 [10–17] mmHg (on 0 [0–2] medications) and from 20 [16–2...
For moderate-to-severe glaucoma, trabeculectomy remains the “gold standard” intraocular pressure (IO...
Background: To determine the efficacy and safety of trabeculectomy with mitomycin-C (trabMMC) compar...
Background/aims: To evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in gla...
Purpose: To compare the effectiveness and safety of the MicroShunt versus trabeculectomy in patients...
For moderate-to-severe glaucoma, trabeculectomy remains the “gold standard” intraocular pressure (IO...
Background: Trabeculectomy is the “gold standard” initial surgical procedure for open-angle glaucoma...
Background Trabeculectomy is the "gold standard " initial surgical procedure for open-angle glaucoma...
Background Trabeculectomy is the "gold standard " initial surgical procedure for open-angle glaucoma...
Objective To compare the two surgical techniques in terms of efficacy, safety, and postoperative man...
Glaucoma unresponsive to medical treatment is managed by surgery. Augmentation with mitomycin C (MMC...
To assess the safety and effectiveness of the PRESERFLO® MicroShunt (formerly InnFocus MicroShunt®) ...
Naoki Tojo, Mitsuya Otsuka, Atsushi Hayashi Department of Ophthalmology, Graduate School of Medicin...
Abstract Glaucoma unresponsive to medical treatment is managed by surgery. Augmentation with mitomyc...
BackgroundGlaucoma is an optic neuropathy that leads to vision loss and blindness. It is the second ...
Background/aims: To evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in gla...
For moderate-to-severe glaucoma, trabeculectomy remains the “gold standard” intraocular pressure (IO...
Background: To determine the efficacy and safety of trabeculectomy with mitomycin-C (trabMMC) compar...
Background/aims: To evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in gla...
Purpose: To compare the effectiveness and safety of the MicroShunt versus trabeculectomy in patients...
For moderate-to-severe glaucoma, trabeculectomy remains the “gold standard” intraocular pressure (IO...
Background: Trabeculectomy is the “gold standard” initial surgical procedure for open-angle glaucoma...
Background Trabeculectomy is the "gold standard " initial surgical procedure for open-angle glaucoma...
Background Trabeculectomy is the "gold standard " initial surgical procedure for open-angle glaucoma...
Objective To compare the two surgical techniques in terms of efficacy, safety, and postoperative man...
Glaucoma unresponsive to medical treatment is managed by surgery. Augmentation with mitomycin C (MMC...
To assess the safety and effectiveness of the PRESERFLO® MicroShunt (formerly InnFocus MicroShunt®) ...
Naoki Tojo, Mitsuya Otsuka, Atsushi Hayashi Department of Ophthalmology, Graduate School of Medicin...
Abstract Glaucoma unresponsive to medical treatment is managed by surgery. Augmentation with mitomyc...
BackgroundGlaucoma is an optic neuropathy that leads to vision loss and blindness. It is the second ...
Background/aims: To evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in gla...
For moderate-to-severe glaucoma, trabeculectomy remains the “gold standard” intraocular pressure (IO...
Background: To determine the efficacy and safety of trabeculectomy with mitomycin-C (trabMMC) compar...
Background/aims: To evaluate 1-year success rates and safety profile of Preserflo™ Microshunt in gla...